Beam Therapeutics Inc. Debt Securities, Available-for-sale
Beam Therapeutics Inc. (BEAM) had Debt Securities, Available-for-sale of $321.38 million as of 2021-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Balance Sheet › Assets › Investments
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2021-11-08
- 2021-09-30: Debt Securities, Available-for-sale $321.38M.
- 2021-06-30: Debt Securities, Available-for-sale $403.26M.
- 2020-12-31: Debt Securities, Available-for-sale $137.50M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2021-09-30 | $321.38M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $403.26M 10-Q · filed 2021-08-10 |
| 2020-12-31 | $137.50M 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |